Alan Walts
Director/Board Member at ELOXX PHARMACEUTICALS, INC.
Net worth: 942 $ as of 2024-03-30
Profile
Alan E.
Walts is the founder of X4 Pharmaceuticals, Inc. (founded in 2013) and Arrakis Therapeutics, Inc. (founded in 2015).
He held the title of Director at both companies.
Dr. Walts is also the founder of Termeer Foundation.
Dr. Walts's current job(s) include being the Executive Chairman at Zikani Therapeutics, Inc. since 2020, the Executive Chairman at PIC Therapeutics, Inc. since 2016, a Director at Artax Biopharma, Inc. since 2017, an Independent Director at Eloxx Pharmaceuticals, Inc. since 2021, and an Independent Director at Neuroelectrics, Inc. Dr. Walts's former job(s) include being the Executive Chairman at Aura Biosciences, Inc. from 2013 to 2019, a Director at Peptimmune, Inc., a Managing Director at Sanofi Ventures from 1986 to 2013, a Director at Proteostasis Therapeutics, Inc., a Director at Valerion Therapeutics LLC, and a Vice President at Genzyme Corp.
Dr. Walts obtained a doctorate degree from Massachusetts Institute of Technology in 1985.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-23 | 942 ( 0.03% ) | 942 $ | 2024-03-30 |
Alan Walts active positions
| Companies | Position | Start |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Director/Board Member | 2021-03-31 |
| Termeer Foundation | Founder | - |
Advent Life Sciences LLP
 Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The private company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Corporate Officer/Principal | 2013-12-31 |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Chairman | 2020-04-30 |
PIC Therapeutics, Inc.
 PIC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology PIC Therapeutics, Inc. operates as a biotechnology company, which focuses on transforming the treatment of cancer though the selective modulation of oncogene translation. The company was founded by Richard Peters and Gerhard Wagner and is headquartered in Boston, MA. | Chairman | 2016-08-31 |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 2012-12-31 |
Neuroelectrics, Inc.
 Neuroelectrics, Inc. Miscellaneous Commercial ServicesCommercial Services Neuroelectrics, Inc. is a company that is developing a therapeutic platform for the treatment of neurological and psychiatric disorders. The company is based in Cambridge, MA and Barcelona, Spain. The company's platform uses neuromodulation, which combines safe and proven neuromodulation capabilities with remote-controlled delivery and personalized treatment protocols to restore and maintain brain health. Neuroelectrics has an expanding pipeline of computationally driven solutions for neurologic and psychiatric disorders. The company was founded by Ana Maiques Valls and Giulio Ruffini, and Ana Maiques Valls has been the CEO since incorporation. | Director/Board Member | - |
Former positions of Alan Walts
| Companies | Position | End |
|---|---|---|
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Founder | 2018-12-31 |
| ░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Alan Walts
| Massachusetts Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 14 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Advent Venture Partners LLP
Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Finance |
Artax Biopharma, Inc.
Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Health Technology |
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Health Technology |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Retail Trade |
Peptimmune, Inc.
 Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Sanofi Ventures
 Sanofi Ventures Investment ManagersFinance Sanofi Ventures (Sanofi) is a venture capital subsidiary of Sanofi founded in 2001. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Valerion Therapeutics LLC
 Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA. | Health Technology |
Advent Life Sciences LLP
Advent Life Sciences LLP BiotechnologyHealth Technology Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The private company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry. | Health Technology |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Health Technology |
PIC Therapeutics, Inc.
PIC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology PIC Therapeutics, Inc. operates as a biotechnology company, which focuses on transforming the treatment of cancer though the selective modulation of oncogene translation. The company was founded by Richard Peters and Gerhard Wagner and is headquartered in Boston, MA. | Health Technology |
Neuroelectrics, Inc.
Neuroelectrics, Inc. Miscellaneous Commercial ServicesCommercial Services Neuroelectrics, Inc. is a company that is developing a therapeutic platform for the treatment of neurological and psychiatric disorders. The company is based in Cambridge, MA and Barcelona, Spain. The company's platform uses neuromodulation, which combines safe and proven neuromodulation capabilities with remote-controlled delivery and personalized treatment protocols to restore and maintain brain health. Neuroelectrics has an expanding pipeline of computationally driven solutions for neurologic and psychiatric disorders. The company was founded by Ana Maiques Valls and Giulio Ruffini, and Ana Maiques Valls has been the CEO since incorporation. | Commercial Services |
| Termeer Foundation |
- Stock Market
- Insiders
- Alan Walts